APO Research
Talk to an analyst

APO RESEARCH · REPORT

Treatments for Alpha-1

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Treatments for Alpha-1 Market Analysis and Forecast 2026-2032

22 December 2025194 pages

Choose your research edition.

Industry ResearchTreatments for Alpha-1 Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Treatments for Alpha-1 Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Treatments for Alpha-1 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Treatments for Alpha-1 Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Treatments for Alpha-1 Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Treatments for Alpha-1 market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Treatments for Alpha-1 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Treatments for Alpha-1 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Treatments for Alpha-1 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Treatments for Alpha-1 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Treatments for Alpha-1 include Takeda, Teva Pharmaceutical Industries, Pfizer, GlaxoSmithKline, Baxter, AstraZeneca, Vertex Pharmaceuticals, ProMetic Life Sciences and Kedrion Group, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Treatments for Alpha-1, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Treatments for Alpha-1, also provides the revenue of main regions and countries. Of the upcoming market potential for Treatments for Alpha-1, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Treatments for Alpha-1 revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Treatments for Alpha-1 market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Treatments for Alpha-1 revenue, projected growth trends, production technology, application and end-user industry.

Treatments for Alpha-1 Segment by Company

Takeda

Teva Pharmaceutical Industries

Pfizer

GlaxoSmithKline

Baxter

AstraZeneca

Vertex Pharmaceuticals

ProMetic Life Sciences

Kedrion Group

Kamada Ltd

Grifols

CSL Behring

Chiesi Pharmaceuticals

Boehringer Ingelheim

Treatments for Alpha-1 Segment by Type

Augmentation Therapy

Diabetes

Cystic Fibrosis(CF)

Non-CF Bronchiectasis(NCFB)

Other

Treatments for Alpha-1 Segment by Application

Hospitals

Specialty Clinics

Pharmacies

Treatments for Alpha-1 Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Treatments for Alpha-1 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Treatments for Alpha-1 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Treatments for Alpha-1.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Treatments for Alpha-1 in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Treatments for Alpha-1 company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Treatments for Alpha-1 revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Treatments for Alpha-1 Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Augmentation Therapy Major Player Table 3. Diabetes Major Player Table 4. Cystic Fibrosis(CF) Major Player Table 5. Non-CF Bronchiectasis(NCFB) Major Player Table 6. Other Major Player Table 7. Global Treatments for Alpha-1 Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospitals Major Player Table 9. Specialty Clinics Major Player Table 10. Pharmacies Major Player Table 11. Treatments for Alpha-1 Industry Trends Table 12. Treatments for Alpha-1 Industry Drivers Table 13. Treatments for Alpha-1 Industry Opportunities and Challenges Table 14. Treatments for Alpha-1 Industry Restraints Table 15. Global Treatments for Alpha-1 Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Treatments for Alpha-1 Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Treatments for Alpha-1 Market Share by Region (2021-2026) Table 18. Global Treatments for Alpha-1 Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Treatments for Alpha-1 Market Share by Region (2027-2032) Table 20. Global Treatments for Alpha-1 Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Treatments for Alpha-1 Revenue Market Share by Players (2021-2026) Table 22. Global Treatments for Alpha-1 Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Treatments for Alpha-1 Key Players Headquarters & Area Served Table 24. Global Treatments for Alpha-1 Players, Product Type & Application Table 25. Global Treatments for Alpha-1 Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Treatments for Alpha-1 by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Treatments for Alpha-1 Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Treatments for Alpha-1 Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Treatments for Alpha-1 Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Treatments for Alpha-1 Revenue Market Share by Type (2021-2026) Table 32. Global Treatments for Alpha-1 Revenue Market Share by Type (2027-2032) Table 33. Global Treatments for Alpha-1 Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Treatments for Alpha-1 Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Treatments for Alpha-1 Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Treatments for Alpha-1 Revenue Market Share by Application (2021-2026) Table 37. Global Treatments for Alpha-1 Revenue Market Share by Application (2027-2032) Table 38. Takeda Company Information Table 39. Takeda Business Overview Table 40. Takeda Treatments for Alpha-1 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Takeda Treatments for Alpha-1 Product Portfolio Table 42. Takeda Recent Development Table 43. Teva Pharmaceutical Industries Company Information Table 44. Teva Pharmaceutical Industries Business Overview Table 45. Teva Pharmaceutical Industries Treatments for Alpha-1 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Teva Pharmaceutical Industries Treatments for Alpha-1 Product Portfolio Table 47. Teva Pharmaceutical Industries Recent Development Table 48. Pfizer Company Information Table 49. Pfizer Business Overview Table 50. Pfizer Treatments for Alpha-1 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Pfizer Treatments for Alpha-1 Product Portfolio Table 52. Pfizer Recent Development Table 53. GlaxoSmithKline Company Information Table 54. GlaxoSmithKline Business Overview Table 55. GlaxoSmithKline Treatments for Alpha-1 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. GlaxoSmithKline Treatments for Alpha-1 Product Portfolio Table 57. GlaxoSmithKline Recent Development Table 58. Baxter Company Information Table 59. Baxter Business Overview Table 60. Baxter Treatments for Alpha-1 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Baxter Treatments for Alpha-1 Product Portfolio Table 62. Baxter Recent Development Table 63. AstraZeneca Company Information Table 64. AstraZeneca Business Overview Table 65. AstraZeneca Treatments for Alpha-1 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. AstraZeneca Treatments for Alpha-1 Product Portfolio Table 67. AstraZeneca Recent Development Table 68. Vertex Pharmaceuticals Company Information Table 69. Vertex Pharmaceuticals Business Overview Table 70. Vertex Pharmaceuticals Treatments for Alpha-1 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Vertex Pharmaceuticals Treatments for Alpha-1 Product Portfolio Table 72. Vertex Pharmaceuticals Recent Development Table 73. ProMetic Life Sciences Company Information Table 74. ProMetic Life Sciences Business Overview Table 75. ProMetic Life Sciences Treatments for Alpha-1 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. ProMetic Life Sciences Treatments for Alpha-1 Product Portfolio Table 77. ProMetic Life Sciences Recent Development Table 78. Kedrion Group Company Information Table 79. Kedrion Group Business Overview Table 80. Kedrion Group Treatments for Alpha-1 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Kedrion Group Treatments for Alpha-1 Product Portfolio Table 82. Kedrion Group Recent Development Table 83. Kamada Ltd Company Information Table 84. Kamada Ltd Business Overview Table 85. Kamada Ltd Treatments for Alpha-1 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Kamada Ltd Treatments for Alpha-1 Product Portfolio Table 87. Kamada Ltd Recent Development Table 88. Grifols Company Information Table 89. Grifols Business Overview Table 90. Grifols Treatments for Alpha-1 Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Grifols Treatments for Alpha-1 Product Portfolio Table 92. Grifols Recent Development Table 93. CSL Behring Company Information Table 94. CSL Behring Business Overview Table 95. CSL Behring Treatments for Alpha-1 Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. CSL Behring Treatments for Alpha-1 Product Portfolio Table 97. CSL Behring Recent Development Table 98. Chiesi Pharmaceuticals Company Information Table 99. Chiesi Pharmaceuticals Business Overview Table 100. Chiesi Pharmaceuticals Treatments for Alpha-1 Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Chiesi Pharmaceuticals Treatments for Alpha-1 Product Portfolio Table 102. Chiesi Pharmaceuticals Recent Development Table 103. Boehringer Ingelheim Company Information Table 104. Boehringer Ingelheim Business Overview Table 105. Boehringer Ingelheim Treatments for Alpha-1 Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Boehringer Ingelheim Treatments for Alpha-1 Product Portfolio Table 107. Boehringer Ingelheim Recent Development Table 108. North America Treatments for Alpha-1 Revenue by Type (2021-2026) & (US$ Million) Table 109. North America Treatments for Alpha-1 Revenue by Type (2027-2032) & (US$ Million) Table 110. North America Treatments for Alpha-1 Revenue by Application (2021-2026) & (US$ Million) Table 111. North America Treatments for Alpha-1 Revenue by Application (2027-2032) & (US$ Million) Table 112. North America Treatments for Alpha-1 Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 113. North America Treatments for Alpha-1 Revenue by Country (2021-2026) & (US$ Million) Table 114. North America Treatments for Alpha-1 Revenue by Country (US$ Million) & (2027-2032) Table 115. Europe Treatments for Alpha-1 Revenue by Type (2021-2026) & (US$ Million) Table 116. Europe Treatments for Alpha-1 Revenue by Type (2027-2032) & (US$ Million) Table 117. Europe Treatments for Alpha-1 Revenue by Application (2021-2026) & (US$ Million) Table 118. Europe Treatments for Alpha-1 Revenue by Application (2027-2032) & (US$ Million) Table 119. Europe Treatments for Alpha-1 Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. Europe Treatments for Alpha-1 Revenue by Country (2021-2026) & (US$ Million) Table 121. Europe Treatments for Alpha-1 Revenue by Country (US$ Million) & (2027-2032) Table 122. China Treatments for Alpha-1 Revenue by Type (2021-2026) & (US$ Million) Table 123. China Treatments for Alpha-1 Revenue by Type (2027-2032) & (US$ Million) Table 124. China Treatments for Alpha-1 Revenue by Application (2021-2026) & (US$ Million) Table 125. China Treatments for Alpha-1 Revenue by Application (2027-2032) & (US$ Million) Table 126. Asia Treatments for Alpha-1 Revenue by Type (2021-2026) & (US$ Million) Table 127. Asia Treatments for Alpha-1 Revenue by Type (2027-2032) & (US$ Million) Table 128. Asia Treatments for Alpha-1 Revenue by Application (2021-2026) & (US$ Million) Table 129. Asia Treatments for Alpha-1 Revenue by Application (2027-2032) & (US$ Million) Table 130. Asia Treatments for Alpha-1 Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 131. Asia Treatments for Alpha-1 Revenue by Region (US$ Million) & (2021-2026) Table 132. Asia Treatments for Alpha-1 Revenue by Region (US$ Million) & (2027-2032) Table 133. SAMEA Treatments for Alpha-1 Revenue by Type (2021-2026) & (US$ Million) Table 134. SAMEA Treatments for Alpha-1 Revenue by Type (2027-2032) & (US$ Million) Table 135. SAMEA Treatments for Alpha-1 Revenue by Application (2021-2026) & (US$ Million) Table 136. SAMEA Treatments for Alpha-1 Revenue by Application (2027-2032) & (US$ Million) Table 137. SAMEA Treatments for Alpha-1 Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 138. SAMEA Treatments for Alpha-1 Revenue by Country (2021-2026) & (US$ Million) Table 139. SAMEA Treatments for Alpha-1 Revenue by Country (US$ Million) & (2027-2032) Table 140. Research Programs/Design for This Report Table 141. Authors List of This Report Table 142. Secondary Sources Table 143. Primary Sources List of Figures Figure 1. Treatments for Alpha-1 Image Figure 2. Global Treatments for Alpha-1 Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Treatments for Alpha-1 Market Size Share 2021 VS 2025 VS 2032 Figure 4. Augmentation Therapy Image Figure 5. Diabetes Image Figure 6. Cystic Fibrosis(CF) Image Figure 7. Non-CF Bronchiectasis(NCFB) Image Figure 8. Other Image Figure 9. Global Treatments for Alpha-1 Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Treatments for Alpha-1 Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospitals Image Figure 12. Specialty Clinics Image Figure 13. Pharmacies Image Figure 14. Global Treatments for Alpha-1 Market Size (US$ Million) & (2021-2032) Figure 15. Global Treatments for Alpha-1 Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Treatments for Alpha-1 Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Treatments for Alpha-1 Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Treatments for Alpha-1 Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Treatments for Alpha-1 Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Treatments for Alpha-1 Revenue Market Share by Type (2021-2032) Figure 22. Global Treatments for Alpha-1 Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Treatments for Alpha-1 Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Treatments for Alpha-1 Revenue Market Share by Application (2021-2032) Figure 25. North America Treatments for Alpha-1 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Treatments for Alpha-1 Revenue Share by Type (2021-2032) Figure 27. North America Treatments for Alpha-1 Revenue Share by Application (2021-2032) Figure 28. North America Treatments for Alpha-1 Revenue Share by Country (2021-2032) Figure 29. United States Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Treatments for Alpha-1 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Treatments for Alpha-1 Revenue Share by Type (2021-2032) Figure 34. Europe Treatments for Alpha-1 Revenue Share by Application (2021-2032) Figure 35. Europe Treatments for Alpha-1 Revenue Share by Country (2021-2032) Figure 36. Germany Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Treatments for Alpha-1 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Treatments for Alpha-1 Revenue Share by Type (2021-2032) Figure 46. China Treatments for Alpha-1 Revenue Share by Application (2021-2032) Figure 47. Asia Treatments for Alpha-1 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Treatments for Alpha-1 Revenue Share by Type (2021-2032) Figure 49. Asia Treatments for Alpha-1 Revenue Share by Application (2021-2032) Figure 50. Asia Treatments for Alpha-1 Revenue Share by Region (2021-2032) Figure 51. Japan Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Treatments for Alpha-1 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Treatments for Alpha-1 Revenue Share by Type (2021-2032) Figure 59. SAMEA Treatments for Alpha-1 Revenue Share by Application (2021-2032) Figure 60. SAMEA Treatments for Alpha-1 Revenue Share by Country (2021-2032) Figure 61. Brazil Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Treatments for Alpha-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Augmentation Therapy
  • Diabetes
  • Cystic Fibrosis(CF)
  • Non-CF Bronchiectasis(NCFB)
  • Other
Applications
  • Hospitals
  • Specialty Clinics
  • Pharmacies
Companies covered
  • Takeda
  • Teva Pharmaceutical Industries
  • Pfizer
  • GlaxoSmithKline
  • Baxter
  • AstraZeneca
  • Vertex Pharmaceuticals
  • ProMetic Life Sciences
  • Kedrion Group
  • Kamada Ltd
  • Grifols
  • CSL Behring
  • Chiesi Pharmaceuticals
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Treatments for Alpha-1 Market by Type
  3. 1.2.1 Global Treatments for Alpha-1 Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Augmentation Therapy
  5. 1.2.3 Diabetes
  6. 1.2.4 Cystic Fibrosis(CF)
  7. 1.2.5 Non-CF Bronchiectasis(NCFB)
  8. 1.2.6 Other
  9. 1.3 Treatments for Alpha-1 Market by Application
  10. 1.3.1 Global Treatments for Alpha-1 Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospitals
  12. 1.3.3 Specialty Clinics
  13. 1.3.4 Pharmacies
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Treatments for Alpha-1 Market Dynamics
  1. 2.1 Treatments for Alpha-1 Industry Trends
  2. 2.2 Treatments for Alpha-1 Industry Drivers
  3. 2.3 Treatments for Alpha-1 Industry Opportunities and Challenges
  4. 2.4 Treatments for Alpha-1 Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Treatments for Alpha-1 Market Perspective (2021-2032)
  2. 3.2 Global Treatments for Alpha-1 Growth Trends by Region
  3. 3.2.1 Global Treatments for Alpha-1 Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Treatments for Alpha-1 Market Size by Region (2021-2026)
  5. 3.2.3 Global Treatments for Alpha-1 Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Treatments for Alpha-1 Revenue by Players
  2. 4.1.1 Global Treatments for Alpha-1 Revenue by Players (2021-2026)
  3. 4.1.2 Global Treatments for Alpha-1 Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Treatments for Alpha-1 Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Treatments for Alpha-1 Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Treatments for Alpha-1 Key Players Headquarters & Area Served
  7. 4.4 Global Treatments for Alpha-1 Players, Product Type & Application
  8. 4.5 Global Treatments for Alpha-1 Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Treatments for Alpha-1 Market CR5 and HHI
  11. 4.6.3 2025 Treatments for Alpha-1 Tier 1, Tier 2, and Tier 3
5 Treatments for Alpha-1 Market Size by Type
  1. 5.1 Global Treatments for Alpha-1 Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Treatments for Alpha-1 Revenue by Type (2021-2032)
  3. 5.3 Global Treatments for Alpha-1 Revenue Market Share by Type (2021-2032)
6 Treatments for Alpha-1 Market Size by Application
  1. 6.1 Global Treatments for Alpha-1 Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Treatments for Alpha-1 Revenue by Application (2021-2032)
  3. 6.3 Global Treatments for Alpha-1 Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda
  2. 7.1.1 Takeda Company Information
  3. 7.1.2 Takeda Business Overview
  4. 7.1.3 Takeda Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Treatments for Alpha-1 Product Portfolio
  6. 7.1.5 Takeda Recent Developments
  7. 7.2 Teva Pharmaceutical Industries
  8. 7.2.1 Teva Pharmaceutical Industries Company Information
  9. 7.2.2 Teva Pharmaceutical Industries Business Overview
  10. 7.2.3 Teva Pharmaceutical Industries Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Teva Pharmaceutical Industries Treatments for Alpha-1 Product Portfolio
  12. 7.2.5 Teva Pharmaceutical Industries Recent Developments
  13. 7.3 Pfizer
  14. 7.3.1 Pfizer Company Information
  15. 7.3.2 Pfizer Business Overview
  16. 7.3.3 Pfizer Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Pfizer Treatments for Alpha-1 Product Portfolio
  18. 7.3.5 Pfizer Recent Developments
  19. 7.4 GlaxoSmithKline
  20. 7.4.1 GlaxoSmithKline Company Information
  21. 7.4.2 GlaxoSmithKline Business Overview
  22. 7.4.3 GlaxoSmithKline Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  23. 7.4.4 GlaxoSmithKline Treatments for Alpha-1 Product Portfolio
  24. 7.4.5 GlaxoSmithKline Recent Developments
  25. 7.5 Baxter
  26. 7.5.1 Baxter Company Information
  27. 7.5.2 Baxter Business Overview
  28. 7.5.3 Baxter Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Baxter Treatments for Alpha-1 Product Portfolio
  30. 7.5.5 Baxter Recent Developments
  31. 7.6 AstraZeneca
  32. 7.6.1 AstraZeneca Company Information
  33. 7.6.2 AstraZeneca Business Overview
  34. 7.6.3 AstraZeneca Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  35. 7.6.4 AstraZeneca Treatments for Alpha-1 Product Portfolio
  36. 7.6.5 AstraZeneca Recent Developments
  37. 7.7 Vertex Pharmaceuticals
  38. 7.7.1 Vertex Pharmaceuticals Company Information
  39. 7.7.2 Vertex Pharmaceuticals Business Overview
  40. 7.7.3 Vertex Pharmaceuticals Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Vertex Pharmaceuticals Treatments for Alpha-1 Product Portfolio
  42. 7.7.5 Vertex Pharmaceuticals Recent Developments
  43. 7.8 ProMetic Life Sciences
  44. 7.8.1 ProMetic Life Sciences Company Information
  45. 7.8.2 ProMetic Life Sciences Business Overview
  46. 7.8.3 ProMetic Life Sciences Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  47. 7.8.4 ProMetic Life Sciences Treatments for Alpha-1 Product Portfolio
  48. 7.8.5 ProMetic Life Sciences Recent Developments
  49. 7.9 Kedrion Group
  50. 7.9.1 Kedrion Group Company Information
  51. 7.9.2 Kedrion Group Business Overview
  52. 7.9.3 Kedrion Group Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Kedrion Group Treatments for Alpha-1 Product Portfolio
  54. 7.9.5 Kedrion Group Recent Developments
  55. 7.10 Kamada Ltd
  56. 7.10.1 Kamada Ltd Company Information
  57. 7.10.2 Kamada Ltd Business Overview
  58. 7.10.3 Kamada Ltd Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Kamada Ltd Treatments for Alpha-1 Product Portfolio
  60. 7.10.5 Kamada Ltd Recent Developments
  61. 7.11 Grifols
  62. 7.11.1 Grifols Company Information
  63. 7.11.2 Grifols Business Overview
  64. 7.11.3 Grifols Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Grifols Treatments for Alpha-1 Product Portfolio
  66. 7.11.5 Grifols Recent Developments
  67. 7.12 CSL Behring
  68. 7.12.1 CSL Behring Company Information
  69. 7.12.2 CSL Behring Business Overview
  70. 7.12.3 CSL Behring Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  71. 7.12.4 CSL Behring Treatments for Alpha-1 Product Portfolio
  72. 7.12.5 CSL Behring Recent Developments
  73. 7.13 Chiesi Pharmaceuticals
  74. 7.13.1 Chiesi Pharmaceuticals Company Information
  75. 7.13.2 Chiesi Pharmaceuticals Business Overview
  76. 7.13.3 Chiesi Pharmaceuticals Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Chiesi Pharmaceuticals Treatments for Alpha-1 Product Portfolio
  78. 7.13.5 Chiesi Pharmaceuticals Recent Developments
  79. 7.14 Boehringer Ingelheim
  80. 7.14.1 Boehringer Ingelheim Company Information
  81. 7.14.2 Boehringer Ingelheim Business Overview
  82. 7.14.3 Boehringer Ingelheim Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Boehringer Ingelheim Treatments for Alpha-1 Product Portfolio
  84. 7.14.5 Boehringer Ingelheim Recent Developments
8 North America
  1. 8.1 North America Treatments for Alpha-1 Revenue (2021-2032)
  2. 8.2 North America Treatments for Alpha-1 Revenue by Type (2021-2032)
  3. 8.2.1 North America Treatments for Alpha-1 Revenue by Type (2021-2026)
  4. 8.2.2 North America Treatments for Alpha-1 Revenue by Type (2027-2032)
  5. 8.3 North America Treatments for Alpha-1 Revenue Share by Type (2021-2032)
  6. 8.4 North America Treatments for Alpha-1 Revenue by Application (2021-2032)
  7. 8.4.1 North America Treatments for Alpha-1 Revenue by Application (2021-2026)
  8. 8.4.2 North America Treatments for Alpha-1 Revenue by Application (2027-2032)
  9. 8.5 North America Treatments for Alpha-1 Revenue Share by Application (2021-2032)
  10. 8.6 North America Treatments for Alpha-1 Revenue by Country
  11. 8.6.1 North America Treatments for Alpha-1 Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Treatments for Alpha-1 Revenue by Country (2021-2026)
  13. 8.6.3 North America Treatments for Alpha-1 Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Treatments for Alpha-1 Revenue (2021-2032)
  2. 9.2 Europe Treatments for Alpha-1 Revenue by Type (2021-2032)
  3. 9.2.1 Europe Treatments for Alpha-1 Revenue by Type (2021-2026)
  4. 9.2.2 Europe Treatments for Alpha-1 Revenue by Type (2027-2032)
  5. 9.3 Europe Treatments for Alpha-1 Revenue Share by Type (2021-2032)
  6. 9.4 Europe Treatments for Alpha-1 Revenue by Application (2021-2032)
  7. 9.4.1 Europe Treatments for Alpha-1 Revenue by Application (2021-2026)
  8. 9.4.2 Europe Treatments for Alpha-1 Revenue by Application (2027-2032)
  9. 9.5 Europe Treatments for Alpha-1 Revenue Share by Application (2021-2032)
  10. 9.6 Europe Treatments for Alpha-1 Revenue by Country
  11. 9.6.1 Europe Treatments for Alpha-1 Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Treatments for Alpha-1 Revenue by Country (2021-2026)
  13. 9.6.3 Europe Treatments for Alpha-1 Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Treatments for Alpha-1 Revenue (2021-2032)
  2. 10.2 China Treatments for Alpha-1 Revenue by Type (2021-2032)
  3. 10.2.1 China Treatments for Alpha-1 Revenue by Type (2021-2026)
  4. 10.2.2 China Treatments for Alpha-1 Revenue by Type (2027-2032)
  5. 10.3 China Treatments for Alpha-1 Revenue Share by Type (2021-2032)
  6. 10.4 China Treatments for Alpha-1 Revenue by Application (2021-2032)
  7. 10.4.1 China Treatments for Alpha-1 Revenue by Application (2021-2026)
  8. 10.4.2 China Treatments for Alpha-1 Revenue by Application (2027-2032)
  9. 10.5 China Treatments for Alpha-1 Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Treatments for Alpha-1 Revenue (2021-2032)
  2. 11.2 Asia Treatments for Alpha-1 Revenue by Type (2021-2032)
  3. 11.2.1 Asia Treatments for Alpha-1 Revenue by Type (2021-2026)
  4. 11.2.2 Asia Treatments for Alpha-1 Revenue by Type (2027-2032)
  5. 11.3 Asia Treatments for Alpha-1 Revenue Share by Type (2021-2032)
  6. 11.4 Asia Treatments for Alpha-1 Revenue by Application (2021-2032)
  7. 11.4.1 Asia Treatments for Alpha-1 Revenue by Application (2021-2026)
  8. 11.4.2 Asia Treatments for Alpha-1 Revenue by Application (2027-2032)
  9. 11.5 Asia Treatments for Alpha-1 Revenue Share by Application (2021-2032)
  10. 11.6 Asia Treatments for Alpha-1 Revenue by Country
  11. 11.6.1 Asia Treatments for Alpha-1 Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Treatments for Alpha-1 Revenue by Country (2021-2026)
  13. 11.6.3 Asia Treatments for Alpha-1 Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Treatments for Alpha-1 Revenue (2021-2032)
  2. 12.2 SAMEA Treatments for Alpha-1 Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Treatments for Alpha-1 Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Treatments for Alpha-1 Revenue by Type (2027-2032)
  5. 12.3 SAMEA Treatments for Alpha-1 Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Treatments for Alpha-1 Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Treatments for Alpha-1 Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Treatments for Alpha-1 Revenue by Application (2027-2032)
  9. 12.5 SAMEA Treatments for Alpha-1 Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Treatments for Alpha-1 Revenue by Country
  11. 12.6.1 SAMEA Treatments for Alpha-1 Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Treatments for Alpha-1 Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Treatments for Alpha-1 Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst